Join Cytel Global HEOR and Real World Evidence Experts

Virtual ISPOR Europe 2021
November 30th – December 3rd, 2021

Our Team of HEOR and RWE experts will be contributing to a number of Issue Panels and Workshops, On Demand Podium presentations, and Poster Sessions taking place at Virtual ISPOR Europe. Connect with our global healthcare stakeholders and stay informed on the latest and greatest happenings in the world of HEOR & RWE.

**Issue Panels and Workshops**

**104K**: Can We ‘Borrow’ Real World Outcomes? What Can We Leverage from Chinese and US Data When Assessing Real World Outcomes for HTA Agreements for Rare Diseases in Europe?

*Radek Wasiak, Paul Arora, Sreeram Ramagopalan, and Mei Yang*

November 30th | 12:30pm - 13:30pm

**303IP**: Do Single-Arm Trials Bring Peril to Network Meta-Analyses (NMAs)?

*Huseyin Naci, Joseph Cappelleri, Dalia Dawoud, and Bart Heeg*

December 2nd | 11:00am - 12:00pm

*For reference all authors relevant to Cytel are bolded.*
On Demand Podium Sessions

Emerging Opportunities for the Use of Real World Data in Comparative Effectiveness Research
**P15: Transcatheter Versus Surgical Aortic Valve Replacement - a Real-World Comparison of Clinical Outcomes Based on a German Claims Dataset**
Fraence Hardtstock, Thomas Wilke, U. Maywald, S. Spitzer
November 22nd | 16:30pm - 16:45pm

Two Years of COVID-19: What Has Been the Global Impact on HRQoL and Clinical Outcomes?
**P64: Evaluating the IMPACT of the COVID-19 Pandemic on Mortality after Myocardial Infarctions Hospitalization in Germany**
Julia Krieger, Fraence Hardtstock, Thomas Wilke, U. Maywald
November 22nd | 16:45pm - 17:00pm

Impact of the COVID-19 Pandemic: Healthcare Utilisation and Outcomes
**P21: Social Distancing and Trends in Influenza Hospitalization during the COVID-19 Outbreak: A Difference-in-Difference Analysis of German Claims DATA**
Scarlette Pacis, U. Maywald, Thomas Wilke, Marco Ghiani
November 22nd | 16:00pm - 16:15pm

Methodological Developments in Survival Analytic Methods to Inform Cost-Effectiveness Models
**P45: The Use of Historical Clinical Trial Data to Inform Survival Extrapolation**
Ha Anh Pham, David Smalbrugge, Florint Kroi, Bart Heeg, Mario Ouwens
November 22nd | 16:00pm - 16:15pm

Methodological Developments in Network Meta-Analysis and Comparative Effectiveness Research
**P44: Novel and Existing Flexible Survival Methods for Network Meta-Analyses**
Andrea Garcia, Andre Verhoek, Sophie Van Beekhuizen, Bart Heeg, M. Postma, S. Roychoudhury, J. Cappelleri, Mario Ouwens
November 22nd | 16:45pm - 17:00pm

*For reference all authors relevant to Cytel are bolded.*
No Specific Diseases

POSC427 - Platform Trials: A Path to Efficient Decision Making and Faster Drug Approvals for Health Technology Assessment Bodies

Noor Zannat, Michael Zoratti, Amruta Radhakrishnan, Mary-Rose Faulkner, Megan Rutherford, Gabriel Tremblay

POSB423 - Incident Versus Prevalent Population: Review of Guidelines to Estimate the Eligible Population for Budget Impact Analysis

Shreena Malaviya, Mike Dolph, Gabriel Tremblay

POSA305 - A Systematic Comparison of the Meta-Analysis Software Landscape and Validation of Metaxact for Meta-Analysis of Sparse Outcomes

Gabriel Tremblay, Patrick Daniele, Behnam Sharif, Yannis Jemiai, Pralay Senchaudhuri, Brinley Zabriskie, Christopher Corcoran

POSB303 - Systematic Review of Probabilistic Sensitivity Analysis Methods in Microsimulation of Chronic Diseases

Behnam Sharif, Megan Rutherford, Raymond Lee, Gabriel Tremblay

POSB310 - The Impact of Small Sample Size on Selecting Appropriate Distributions for Parametric Survival Extrapolations Models: A Methodological Commentary and Simulation Study

Michael Groff, Gabriel Tremblay, Patrick Daniele

POSC426 - Evaluating the Impact of Strong Covariate Imbalance on Population Adjusted Indirect Treatment Comparisons: A Simulation Study

Michael Groff, Gabriel Tremblay, Patrick Daniele

POSB311 - Reviewing the Use of Matching Adjusted Indirect Comparisons in Health Technology Assessment Submissions

Sanghee Hwang, Michael Groff, Patrick Daniele, Gabriel Tremblay

*For reference all authors relevant to Cytel are bolded.*
## Oncology

**POSA422 - The Impact of Congress Abstracts on Overall Publications in Acute Myeloid Leukemia (AML): Results of a Systematic Literature Review**  
*Alyssa Moreau, Marie-Eve Richard, Sharada Harricharan, Anna Forsythe*

**POSA421 - Understanding the Impact of Congress Abstracts on Overall Publications in Multiple Myeloma (MM) - Results of a Systematic Literature Review (SLR)**  
*Alyssa Moreau, Marie-Eve Richard, Sharada Harricharan, Anna Forsythe*

**POSB292 - Strategic Considerations for Future Indirect Treatment Comparisons (ITCS) in Advanced or Metastatic Melanoma: An EARLY Feasibility Assessment Study**  
*Katherine Appiah, Andrea Garcia, Maria Rizzo*

**POSA303 - Influence of Treatment Effect on Parameters in Fractional Polynomials for Network Meta-Analyses**  
*Donata Freigofaite, Andre Verhoek, Bart Heeg*

**POSA428 - The Impact of Treatment Effect Parameterization in Mixture Cure Models on Survival Estimates and Uncertainty**  
*Talitha Vincken, Zainab Al-Khayat, Andre Verhoek, Bart Heeg, M. Ouwens*

**POSA321 - Estimating Correlations Between Relative Efficacy of Immuno-Oncology Monotherapies Across Four Oncology Indications**  
*Andreas Freitag, M. Ract, I. Altaf-Haroon, S. Dodman, V. Kapetanakis*

---

## Respiratory Related Disorders

**POSA32 - Early COVID-19 Pandemic in Germany: Patient Characteristics and Clinical Outcomes**  
*Scarlette Pacis, U. Maywald, Thomas Wilke, Marco Ghiani*

**POSA52 - A Year-on-Year Comparison Overall German Healthcare Resource Utilization in COVID Versus Non-COVID Times: A German Claims Data Analysis**  
*Antje Mevius, Sabrina Müller, Thomas Wilke, U. Maywald*

**POSA424 - Challenges of COVID-19 Research: Results from a Systematic Literature Review on COVID-19 and Asthma or COPD**  
*Stacy Grieve, Patrick Daniele, Adrian Paul Rabe, Anna Forsythe*

---

## Drugs

**POSA303 - Influence of Treatment Effect on Parameters in Fractional Polynomials for Network Meta-Analyses**  
*Donata Freigofaite, Andre Verhoek, Bart Heeg*

**POSA125 - Comparing Healthcare Cost Among Empagliflozin, DPP-4 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A German Claims Data Analysis**  
*Thomas Wilke, A. Stuermlinger, Nils Picker, Sabrina Müller, B. Deiters, Axel Dittmar, J. Aberle, M. Gabler*

---

## Rare and Orphan Diseases

**POSB258 - Evaluation of the Current Impact of Indirect Treatment Comparisons (ITCS) to Support Health Technology Assessments (HTAS) in Rare Diseases**  
*Mihaela Musat, Anna Forsythe, Sharada Harricharan*

*For reference all authors relevant to Cytel are bolded.*
Access a wealth of information, publications and Cytel HEOR resources at the new ISPOR HEOR Solutions Center. Connect with our global community of healthcare stakeholders and stay informed on the latest and greatest happenings in the world of HEOR. #ISPOREurope

**POSTERS**

**Urinary/Kidney Disorders**

**POSC25** - Comparative Efficacy of Abobotulinumtoxina for the Treatment of Refractory Neurogenic Detrusor Overactivity: An Indirect Treatment Comparison  

*N. Danchenko, K. Fahrbach, Andreas Freitag, J. Tarpey, J. Whalen*

**Gastrointestinal Disorders**

**POSB227** - The Frequency of Statin Use in German Patients with Ulcerative Colitis: A Cross-Sectional Analysis of Prevalent Cases Using a Large Retrospective Claims Database  

*Axel Dittmar, Sabrina Müller, A. Cerani, Thomas Wilke*

**Mental Health**

**POSB189** - Mental Health in COVID Times: A Quasi-Experimental Analysis of the Impact of Lockdown Measures on Mental Healthcare Use in Germany  

*Marco Ghiani, Thomas Wilke*

**POSC74** - Considerations for Mental Health Effects in Health Economic Analyses  

*Mike Dolph, Gabriel Tremblay*

**Neurological Disorders**

**POSC25** - Comparative Efficacy of Abobotulinumtoxina for the Treatment of Refractory Neurogenic Detrusor Overactivity: An Indirect Treatment Comparison  

*N. Danchenko, K. Fahrbach, Andreas Freitag, J. Tarpey, J. Whalen*

*For reference all authors relevant to Cytel are bolded.*